Viking Therapeutics Inc. (VKTX)
Is Viking Therapeutics a Buy on the Dip?
Viking stock has slipped more than 20% from its peak.
Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
All signs are pointing toward its continued success.
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions.
ATTENTION Viking Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.
Why Viking Therapeutics Stock Plummeted After Soaring Today
Are we ready for the Great Obesity Drug Gold Rush of the 2020s?
Viking Therapeutics soars then drops on obesity data
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell the news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025.
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics reports encouraging results from weightloss tablet
Viking Therapeutics (NASDAQ:VKTX) shares jumped then fell after it reported results from a trial of its weightloss tablet. The San Diego company said its phase-one clinical trial of an oral tablet formulation of its VK2735 tablet dosed daily for 28 days resulted in up to 8.2% mean weight loss for some patients, or 6.8% versus a placebo.
